In the video, Milana D sounded like she was ready to get
In the video, Milana D sounded like she was ready to get the Tnbc trial going! (Did anyone catch that)?
"But getting IRB approval takes time etc etc".
Cause I'm pretty sure she would like to get her patients enrolled.
If the typical time frame is 48 day upreg from baseline. Dr J mentioned a tnbc protocol of initial course of several weeks leron/chemo with immediate ICI for some of the patients. And delayed ici treatment for others .
Would this end up as basically a 60 day leron followed by ici vs some delay for others with a one year trial for each patient with follow up observation for a year?
I really want to put the pressure on potential partners by getting it going.
What i am waiting for now.
-The exact protocol for mcrc ici rollover and which/s ici (I've been looking around to see if anything pops up hinting it's complete)
-2 abstracts
- I would like to hear about our eind patient who should have reached 6 months minimum ici treatment.(hope she's progressing well!)
-The 20 patient dsmb 700mg approval
Will any of these likely be pr'd.
Maybe some maybe no others.
And I am super ready to get tnbc started. More than Milana i bet.
I know that mcrc took from initial fda discussions Aug 2024, fda agreement was Nov 2024 and first patient June + - 2025.
How quickly in a best case scenario could it get going.
Who knows I guess
We need a partner yo.
12
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Nvidia's stock surged in 2023 like a rocket ship headed to the moon, making traders sit up and take notice. With its reputation firmly planted in tech innovation, it managed to pull off a jaw-dropping comeback after a sell-off earlier in the year. Resilience Amidst Market Whirlwind This wasn't just any bounce-back; we’re talking about a solid 13% uptick in weeks when...
Continue Reading
Yoshiharu Global Co. Announces a Significant Stock Split Yoshiharu Global Co. (NASDAQ: YOSH), an innovative restaurant operator specializing in authentic Japanese ramen and rolls, has made an important announcement regarding its stock. The company’s Board of Directors has authorized a 4-for-1 forward stock split to enhance shareholder engagement and market activity....
Continue Reading
Viatris Sets Pricing for Senior Notes Tender Offers Viatris Inc. (NASDAQ: VTRS) is moving ahead with cash tender offers for certain senior notes and has announced the pricing terms. The effort is part of a broader plan to streamline outstanding debt and sharpen the company’s financial profile. In practical terms, Viatris is offering to buy back targeted notes for cash...
Continue Reading
AB Akola Group's Ambitious Expansion Plans AB Akola Group, one of the prominent agricultural and food production organizations in the Baltic region, is gearing up for an exciting chapter of growth and innovation. With ownership of the well-known company Kauno Gr?dai, the group is focusing on enhancing its production capabilities to remain competitive in the market. A...
Continue Reading
A Surge in Paraxylene Demand Ahead The global market for paraxylene, a crucial compound in the production of polyester fibers and PET resin, is witnessing significant growth. Market analysts predict that the volume could reach a staggering 96.40 million tons by 2034, marking a steady growth rate of 4.59% annually from the year 2025 onwards. The driving forces behind this...
Continue Reading